Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …

Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …

Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

Background Failures in drug trials strengthen the necessity to further determine the
neuropathological events during the development of Alzheimer's disease (AD). We sought to …

Introduction We tested how tube types (ethylenediaminetetraacetic acid [EDTA], serum,
lithium heparin [LiHep], and citrate) and freeze–thaw cycles affect levels of blood biomarkers …

Plasma biomarkers for neurodegenerative disorders: ready for... : Current Opinion in
Psychiatry Plasma biomarkers for neurodegenerative disorders: ready for prime time …

Objective Reactive astrogliosis is a hallmark of Alzheimer's disease (AD) and frontotemporal
dementia (FTD) but differences between the diseases and time course are unclear. Here, we …